Exicure, Inc. (2H0A.F)
| Previous close | 0.3280 |
| Open | 0.2960 |
| Bid | 0.2840 x N/A |
| Ask | 0.3320 x N/A |
| Day's range | 0.2960 - 0.2960 |
| 52-week range | 0.2660 - 1.3000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 2.66M |
| Beta (5Y monthly) | 1.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Exicure, Inc. Reports Full Year 2023 Financial Results
CHICAGO, June 06, 2024--Exicure, Inc. Reports Full Year 2023 Financial Results
- Business Wire
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
CHICAGO, May 23, 2024--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received notice of a delisting determination (the "Staff Delisting Determination") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"). The Staff Delisting Determination notified the Company that since it has not yet filed its Form 10-K for the year ended December 31, 2023 (the "Form 10-K") per Nasdaq Listing Rule 5250(c)(1) (the "Rule") by Nasdaq’s extended deadl
- Business Wire
Exicure, Inc. Reports Third Quarter 2023 Financial Results
CHICAGO, May 16, 2024--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value.
